Welcome to our dedicated page for Jasper Therapeutics SEC filings (Ticker: JSPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Jasper Therapeutics, Inc. (JSPR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed clinical-stage biotechnology issuer. Jasper files reports and current updates with the U.S. Securities and Exchange Commission in connection with its development of briquilimab, an aglycosylated monoclonal antibody targeting KIT (CD117) for chronic mast cell diseases such as chronic urticaria and asthma.
Current Reports on Form 8-K featured here include items on quarterly financial results and corporate updates, public offerings of common stock, pre-funded warrants and common warrants, and material corporate actions such as workforce reductions and operating plan changes. These filings describe how Jasper intends to use offering proceeds to advance preclinical and clinical development of briquilimab in mast cell driven diseases and to fund general corporate purposes.
Filings also disclose Nasdaq listing details for Jasper’s voting common stock (trading symbol JSPR) and redeemable warrants (trading symbol JSPRW), as well as information on shareholder meetings, director elections, advisory votes on executive compensation and the appointment of the independent registered public accounting firm. Selected 8-Ks incorporate press releases that summarize clinical data from the BEACON study in chronic spontaneous urticaria, the ETESIAN study in allergic asthma and related open-label extension work, along with safety and efficacy observations.
On Stock Titan, these SEC documents are paired with AI-powered tools that help readers quickly identify key sections, such as financing terms, use of proceeds, study-related disclosures and governance decisions. Users can review Jasper’s historical and recent filings to understand the company’s reporting history, capital structure developments and the regulatory context for its briquilimab clinical programs.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC report beneficial ownership of 1,764,848 shares of Jasper Therapeutics voting common stock, representing 6.3% of the class. They have shared voting and shared dispositive power over all of these shares, with no sole authority.
The firms state that the securities were acquired and are held in the ordinary course of business and not to change or influence control of Jasper Therapeutics. A joint filing agreement confirms that both entities are reporting together, with signatures provided by an attorney-in-fact dated January 6, 2026.
Morgan Stanley filed a Schedule 13G reporting a significant ownership position in Jasper Therapeutics, Inc. voting common stock. Morgan Stanley reports beneficial ownership of 1,969,785 shares, representing 7.0% of the class, with shared voting and shared dispositive power over these shares.
Affiliated entity Morgan Stanley Capital Services LLC reports beneficial ownership of 1,903,420 shares, or 6.8% of the class, also with shared voting and dispositive power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Jasper Therapeutics.
Jasper Therapeutics CEO and President Jeetinder Singh Mahal received a stock option covering 500,000 shares of voting common stock on February 6, 2026. The option has an exercise price of $1.35 per share and expires on February 6, 2036.
According to the vesting terms, one quarter of the option vests on February 6, 2027, with the remaining three quarters vesting in equal monthly installments over the following 36 months, conditioned on continued service with the company.
A shareholder group associated with Anders Hove filed an amended Schedule 13G reporting beneficial ownership of 1,486,492 shares of Jasper Therapeutics, Inc. common stock, equal to 5.3% of the class. This ownership is held through investment entities including Acorn Bioventures, L.P. and Acorn Bioventures 2, L.P., with related general partners Acorn Capital Advisors GP, LLC and Acorn Capital Advisors GP 2, LLC. The percentages are based on 27,984,039 shares of common stock outstanding as of November 6, 2025. The reporting persons certify the shares were not acquired and are not held for the purpose of changing or influencing control of Jasper Therapeutics.
Jasper Therapeutics, Inc. reported that it has released a press release with positive updated clinical data from its BEACON Phase 1b/2a study of subcutaneous briquilimab in adult participants with chronic spontaneous urticaria, along with data from an open-label extension study in chronic spontaneous and chronic inducible urticaria. The company is also hosting a conference call and webinar at 8:00 a.m. Eastern Time on January 8, 2026 to present these updated BEACON and open-label extension results. The press release and the related investor presentation are provided as exhibits to this report.
Jasper Therapeutics reported leadership changes, with the Board determining that, effective January 5, 2026, Ron Martell would cease serving as Chief Executive Officer and President. Under his amended employment agreement, this termination is treated as without cause, and he is eligible for 18 months of base salary and up to 18 months of COBRA premium payments, subject to signing a release in favor of the company.
Effective the same date, the Board appointed current Chief Operating Officer Jeet Mahal as Chief Executive Officer and President and as a Class III director, making him the company’s principal executive officer. His annualized salary was increased to $600,000, and he is eligible for an annual performance bonus of up to 50% of base salary, with future compensation adjustments at the Compensation Committee’s discretion. The Board also named current Chairperson Thomas G. Wiggans as Executive Chair, further formalizing his leadership role.
Jasper Therapeutics (JSPR) filed its Q3 2025 report, highlighting continued losses and liquidity pressure with a going concern warning. The company reported a net loss of $18.7 million for the quarter and $66.7 million for the nine months ended September 30, 2025. Cash and cash equivalents were $50.9 million as of September 30, 2025, while operating cash outflows reached $55.3 million over nine months.
To bolster liquidity, Jasper completed an underwritten offering in September, receiving net proceeds of $27.5 million and issuing 11,670,707 common shares, 675,000 pre-funded warrants, and 12,345,707 common warrants with a $2.92 exercise price. Year to date, it also sold 1,231,447 shares via its ATM for $6.5 million. A new warrant liability of $22.6 million was recognized at quarter end.
Jasper reorganized to extend runway, reducing its workforce by about 50% (20 employees) and recording $1.8 million in restructuring costs. It halted enrollment in its Phase 1b/2a asthma study and discontinued SCID and remaining investigator-sponsored programs to focus on briquilimab in chronic urticaria. Shares outstanding were 27,984,039 as of November 6, 2025.
Jasper Therapeutics (JSPR) furnished an 8-K announcing it issued a press release reporting financial results for the quarter ended September 30, 2025, along with a corporate update.
The release is attached as Exhibit 99.1 and was furnished under Item 2.02 and Item 9.01. The company notes this information is being furnished and not deemed filed under Section 18 of the Exchange Act or incorporated by reference, except as expressly set forth.
Lucas Svetlana, a director of Jasper Therapeutics, Inc. (JSPR), reported purchases on 09/22/2025 of 20,000 shares of voting common stock together with 20,000 warrants in an underwritten public offering at a combined purchase price of $2.43 per share and accompanying warrant. Following the transaction she beneficially owns 20,000 shares. The warrants have an exercise price of $2.92, are exercisable beginning 03/22/2026, and expire 03/22/2030. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 09/24/2025.
FAQ
What is the current stock price of Jasper Therapeutics (JSPR)?
What is the market cap of Jasper Therapeutics (JSPR)?
